Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Infectious Diseases |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702021000200205 |
Resumo: | ABSTRACT Objectives: To assess the efficacy of hydroxychloroquine in combination with azithromycin in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse events. Method: Retrospective comparative study, based in a quaternary private hospital in Rio de Janeiro, Brazil, involving 193 adult patients hospitalized for mild and moderate COVID-19 related ARSD, analyzing treatment efficacy based on clinical and biochemical outcomes. Results: The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was 59 (47–70) in the active group and 65 (47−77) in the control group (p < 0.05). Patients in the control group had greater extent of pulmonary involvement on baseline chest CT scans (p < 0.05). All other baseline variables (BMI, comorbidities, previous use of medications and biochemical assessments) were similar between groups. In the medication group, 25% (25 out of 101) were admitted to the ICU, compared to 21% (19 out of 92) in the control group (p > 0.05). No difference in mortality, duration of non-invasive oxygen use or duration of hospitalization was seen between groups. The therapeutic regimen was well tolerated, with only eight (7.9%) patients presenting gastrointestinal symptoms and eight (7.9%) patients withdrawn treatment due to QTc prolongation. Conclusions: Patients treated with hydroxychloroquine combined with azithromycin and the control group had similar clinical outcomes. This therapeutic regimen was considered ineffective in hospitalized patients with mild to moderate COVID-19 related ARDS and was associated with few non-severe adverse events. |
id |
BSID-1_0f719cbf78938e9723537c56418461b1 |
---|---|
oai_identifier_str |
oai:scielo:S1413-86702021000200205 |
network_acronym_str |
BSID-1 |
network_name_str |
Brazilian Journal of Infectious Diseases |
repository_id_str |
|
spelling |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19COVID-19Severe acute respiratory syndrome coronavirus 2HydroxychloroquineAzithromycinABSTRACT Objectives: To assess the efficacy of hydroxychloroquine in combination with azithromycin in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse events. Method: Retrospective comparative study, based in a quaternary private hospital in Rio de Janeiro, Brazil, involving 193 adult patients hospitalized for mild and moderate COVID-19 related ARSD, analyzing treatment efficacy based on clinical and biochemical outcomes. Results: The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was 59 (47–70) in the active group and 65 (47−77) in the control group (p < 0.05). Patients in the control group had greater extent of pulmonary involvement on baseline chest CT scans (p < 0.05). All other baseline variables (BMI, comorbidities, previous use of medications and biochemical assessments) were similar between groups. In the medication group, 25% (25 out of 101) were admitted to the ICU, compared to 21% (19 out of 92) in the control group (p > 0.05). No difference in mortality, duration of non-invasive oxygen use or duration of hospitalization was seen between groups. The therapeutic regimen was well tolerated, with only eight (7.9%) patients presenting gastrointestinal symptoms and eight (7.9%) patients withdrawn treatment due to QTc prolongation. Conclusions: Patients treated with hydroxychloroquine combined with azithromycin and the control group had similar clinical outcomes. This therapeutic regimen was considered ineffective in hospitalized patients with mild to moderate COVID-19 related ARDS and was associated with few non-severe adverse events.Brazilian Society of Infectious Diseases2021-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702021000200205Brazilian Journal of Infectious Diseases v.25 n.2 2021reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1016/j.bjid.2021.101549info:eu-repo/semantics/openAccessLamback,Elisa BaranskiOliveira,Monica Amorim deHaddad,Andrea FerreiraVieira,André Filipe MarcondesFerreira Neto,Armando LeãoMaia,Taciana da SilvaChrisman,Juliana de RezendeSpineti,Pedro Pimenta de MelloMattos,Marco Antonio deCosta,Eduardoeng2021-06-16T00:00:00Zoai:scielo:S1413-86702021000200205Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2021-06-16T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false |
dc.title.none.fl_str_mv |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 |
title |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 |
spellingShingle |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 Lamback,Elisa Baranski COVID-19 Severe acute respiratory syndrome coronavirus 2 Hydroxychloroquine Azithromycin |
title_short |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 |
title_full |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 |
title_fullStr |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 |
title_full_unstemmed |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 |
title_sort |
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 |
author |
Lamback,Elisa Baranski |
author_facet |
Lamback,Elisa Baranski Oliveira,Monica Amorim de Haddad,Andrea Ferreira Vieira,André Filipe Marcondes Ferreira Neto,Armando Leão Maia,Taciana da Silva Chrisman,Juliana de Rezende Spineti,Pedro Pimenta de Mello Mattos,Marco Antonio de Costa,Eduardo |
author_role |
author |
author2 |
Oliveira,Monica Amorim de Haddad,Andrea Ferreira Vieira,André Filipe Marcondes Ferreira Neto,Armando Leão Maia,Taciana da Silva Chrisman,Juliana de Rezende Spineti,Pedro Pimenta de Mello Mattos,Marco Antonio de Costa,Eduardo |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Lamback,Elisa Baranski Oliveira,Monica Amorim de Haddad,Andrea Ferreira Vieira,André Filipe Marcondes Ferreira Neto,Armando Leão Maia,Taciana da Silva Chrisman,Juliana de Rezende Spineti,Pedro Pimenta de Mello Mattos,Marco Antonio de Costa,Eduardo |
dc.subject.por.fl_str_mv |
COVID-19 Severe acute respiratory syndrome coronavirus 2 Hydroxychloroquine Azithromycin |
topic |
COVID-19 Severe acute respiratory syndrome coronavirus 2 Hydroxychloroquine Azithromycin |
description |
ABSTRACT Objectives: To assess the efficacy of hydroxychloroquine in combination with azithromycin in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse events. Method: Retrospective comparative study, based in a quaternary private hospital in Rio de Janeiro, Brazil, involving 193 adult patients hospitalized for mild and moderate COVID-19 related ARSD, analyzing treatment efficacy based on clinical and biochemical outcomes. Results: The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was 59 (47–70) in the active group and 65 (47−77) in the control group (p < 0.05). Patients in the control group had greater extent of pulmonary involvement on baseline chest CT scans (p < 0.05). All other baseline variables (BMI, comorbidities, previous use of medications and biochemical assessments) were similar between groups. In the medication group, 25% (25 out of 101) were admitted to the ICU, compared to 21% (19 out of 92) in the control group (p > 0.05). No difference in mortality, duration of non-invasive oxygen use or duration of hospitalization was seen between groups. The therapeutic regimen was well tolerated, with only eight (7.9%) patients presenting gastrointestinal symptoms and eight (7.9%) patients withdrawn treatment due to QTc prolongation. Conclusions: Patients treated with hydroxychloroquine combined with azithromycin and the control group had similar clinical outcomes. This therapeutic regimen was considered ineffective in hospitalized patients with mild to moderate COVID-19 related ARDS and was associated with few non-severe adverse events. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702021000200205 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702021000200205 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.bjid.2021.101549 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
Brazilian Journal of Infectious Diseases v.25 n.2 2021 reponame:Brazilian Journal of Infectious Diseases instname:Brazilian Society of Infectious Diseases (BSID) instacron:BSID |
instname_str |
Brazilian Society of Infectious Diseases (BSID) |
instacron_str |
BSID |
institution |
BSID |
reponame_str |
Brazilian Journal of Infectious Diseases |
collection |
Brazilian Journal of Infectious Diseases |
repository.name.fl_str_mv |
Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID) |
repository.mail.fl_str_mv |
bjid@bjid.org.br||lgoldani@ufrgs.br |
_version_ |
1754209245172072448 |